Robert Strong is a Psychiatry physician. OpenAlex indexes 17 publications with 986 citations (h-index 13).
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
50 N Medical Dr
Salt Lake City, UT 841320001
Telephone
801-581-7951Registry record last updated 8 Jul 2007.
Industry payments
6 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Otsuka America Pharmaceutical, Inc.Program year20252 payments
- ABBVIE INC.Program year20251 payment
- Neurocrine BioSciences, Inc.Program year20251 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Nervous system
95.4%Benzodiazepine23.3%Lorazepam33%Clonazepam30%Alprazolam24%Temazepam9%Diazepam4%Part D<11 patientsAtypical Antipsychotic15%Quetiapine Fumarate39%Olanzapine26%Aripiprazole18%Lurasidone Hcl9%Paliperidone Er8%Part D<11 patients+ 18 more classes in this area
Cardiovascular
3.6%alpha-Adrenergic Blocker1.3%Prazosin Hcl100%Part D<11 patientsBeta blocker1.2%Propranolol Hcl100%Part D<11 patients+ 1 more class in this area
Metabolism & gastrointestinal
1%H2 blocker1%Famotidine100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Long-term open-label response to atomoxetine in adult ADHD: influence of sex, emotional dysregulation, and double-blind response to atomoxetine
ADHD Attention Deficit and Hyperactivity Disorders
2011 - Oros Methylphenidate in the Treatment of Adults with Adhd: A 6-Month, Open-Label, Follow-Up Study
Annals of Clinical Psychiatry
2010 - Personality Disorders in Adhd Part 3: Personality Disorder, Social Adjustment, and Their Relation to dimensions of Adult Adhd
Annals of Clinical Psychiatry
2010
Similar KOLs
Other experts from the same institution or the same specialty.
Philip Scheltens
Inserm
Rafael Tabarés‐Seisdedos
Universitat de València
Nick C. Fox
UK Dementia Research Institute
Perminder S. Sachdev
Department of Health and Aged Care
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”